TRIENTINE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIENTINE HYDROCHLORIDE (TRIENTINE HYDROCHLORIDE).
Trientine hydrochloride chelates and promotes the urinary excretion of copper. It forms a stable complex with copper, which is then eliminated via the kidneys, reducing copper accumulation in tissues.
| Metabolism | Trientine is not significantly metabolized; it is primarily excreted unchanged in urine. |
| Excretion | Renal: ~50% (as unchanged drug and metabolites); Biliary/Fecal: ~35%; Minor metabolism; total clearance ~30 L/hr. |
| Half-life | Terminal half-life: 8-10 hours (single dose); 4-6 hours after multiple dosing due to enzyme induction; clinical context: requires thrice daily dosing. |
| Protein binding | ~50-60% bound to albumin and gamma globulins; minor binding to other plasma proteins. |
| Volume of Distribution | Vd: 1.3-1.5 L/kg; suggests extensive distribution into total body water and tissues, including high copper storage sites. |
| Bioavailability | Oral: ~70-80% (variable, 60-90% depending on formulation and food effect); food reduces absorption by ~30%. |
| Onset of Action | Oral: ~1-2 hours (peak plasma concentration); clinical effect (copper excretion) begins within hours, full effect by 1-2 weeks. |
| Duration of Action | Copper chelation effect: 8-12 hours after oral dose; requires TID dosing to maintain continuous copper excretion. |
250-500 mg orally 4 times daily, 1 hour before or 2 hours after meals and at least 1 hour apart from other medications, food, or milk.
| Dosage form | CAPSULE |
| Renal impairment | No specific dose adjustments recommended. Use with caution in severe renal impairment; monitor for potential accumulation. |
| Liver impairment | No specific dose adjustments recommended based on Child-Pugh score. Use with caution in severe hepatic impairment. |
| Pediatric use | For Wilson disease: 20 mg/kg/day orally, divided into 2-3 doses, not to exceed 1500 mg/day. Administer on empty stomach. |
| Geriatric use | No specific dose adjustments. Start at lower end of dosing range; monitor renal function and for potential adverse effects due to age-related decline in organ function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRIENTINE HYDROCHLORIDE (TRIENTINE HYDROCHLORIDE).
| Breastfeeding | It is not known whether trientine is excreted in human milk. The M/P ratio is not available. Given the potential for copper deficiency in the infant, caution is advised. The manufacturer recommends discontinuing breastfeeding or the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Based on limited human data, trientine hydrochloride is not associated with major teratogenic effects. However, since copper deficiency can result from therapy, and copper is essential for fetal development, caution is warranted. The drug should be used during pregnancy only if clearly needed. No specific trimester risks are established; the primary concern is potential copper deficiency leading to fetal harm. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to trientine or any component of the formulation.","Rheumatoid arthritis (not indicated and may worsen).","Cystinuria (not indicated)."]
| Precautions | ["May cause iron deficiency anemia due to chelation of iron; monitor iron levels.","Neurological deterioration may occur initially in some patients with Wilson disease.","Monitor for hypersensitivity reactions.","Use with caution in patients with renal impairment as drug is renally eliminated."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum copper and ceruloplasmin levels to avoid copper deficiency. Assess for signs of anemia, leukopenia, or thrombocytopenia due to possible bone marrow suppression. In pregnancy, monitor fetal growth and development via ultrasound. Monitor maternal neurologic and hepatic status as appropriate for Wilson disease. |
| Fertility Effects | Animal studies have not shown impaired fertility. In humans, no specific data on fertility effects are available. Since Wilson disease can affect fertility, treatment with trientine may improve fertility by controlling copper overload. |